Obesity Drug Shortage Ends for Lilly, Continues for Novo as Industry Bolsters Manufacturing

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the insatiable demand for weight loss drugs.